Alpha Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Alpha Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.98M	Sell	4,778 -50	-1%	-$34K	0.39%	68
2026 Q1	$3.73M	Sell	4,828 -565	-10%	-$433K	0.54%	57
2025 Q4	$4.16M	Sell	5,393 -119	-2%	-$80.8K	0.59%	57
2025 Q3	$3.1M	Buy	5,512 +36	+0.7%	+$20.4K	0.49%	64
2025 Q2	$2.87M	Buy	5,476 +1,966	+56%	+$1.1M	0.5%	64
2025 Q1	$2.23M	Buy	3,510 +363	+12%	+$250K	0.42%	68
2024 Q4	$2.24M	Buy	3,147 +1,912	+155%	+$1.6M	0.41%	67
2024 Q3	$1.3M	Buy	+1,235	New	+$1.37M	0.24%	69
2021 Q1	–	Sell	-554	Closed	-$268K	–	118
2020 Q4	$268K	Sell	554 -570	-51%	-$308K	0.07%	99
2020 Q3	$629K	Buy	1,124 +671	+148%	+$407K	0.18%	79
2020 Q2	$283K	Buy	+453	New	+$257K	0.1%	91

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Alpha Capital Management's REGN Position: Q2 2026 in Review

Alpha Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1% in Q2 2026, selling an estimated $34K and leaving 4,778 shares worth $2.98M. The position accounts for 0.39% of the portfolio, ranked #68.

Alpha Capital Management first reported a position in REGN in Q2 2020 and has held it in 11 quarters since. The position peaked at $4.16M in Q4 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Alpha Capital Management held 4,778 shares of Regeneron Pharmaceuticals worth $2.98M as of Q2 2026.
Alpha Capital Management sold 50 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $34K.
Regeneron Pharmaceuticals made up 0.39% of Alpha Capital Management's portfolio in Q2 2026, its #68 holding.
Alpha Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
Alpha Capital Management's Regeneron Pharmaceuticals position peaked at $4.16M in Q4 2025.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Alpha Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.